Early clinical investigations of TIM-3 targeting mAbs have predominantly focused on combinations with PD-1/PD-L1 inhibitors, a strategy underpinned by the co-expression of these receptors on severely exhausted T cells, especially in tumor resistance prior to a checkpoint blockade. The gene discussed is HAVCR2; the disease is neoplasm.